-
-
-
-
-
-
News
-
-
Contact UsThe company focuses on the research, development, production, and sales of chemical raw materials and their formulations. All products have passed national GMP certification, and core products have successively passed official pharmaceutical regulatory certifications from multiple countries, including the EU EDQM, US FDA, Japanese PMDA, and South Korean MFDS. Following its successful listing on the Shenzhen Stock Exchange's ChiNext board on April 4, 2023, Keyuan Pharmaceutical has entered a phase of rapid development driven by both digital intelligence and capital, with its business spanning dozens of countries and regions worldwide.
Keyuan Pharmaceutical Holds Special Meeting on International Registration Promotion, Accelerating the Company's Global Expansion!
Publish Time:
2024-08-27
To accelerate the entry of several company products into international markets and further enhance the competitive edge of "industrial globalization," Keyuan Pharmaceutical (stock code: 301281.SZ) recently held a special international registration conference. Senior management, the R&D team, and international registration experts gathered together to jointly discuss and map out implementation strategies for the international registration of multiple company products, providing robust product support to continuously boost Keyuan Pharmaceutical's export revenue.
To accelerate the entry of several company products into international markets and further enhance the competitive edge of "industrial globalization," Keyuan Pharmaceutical (stock code: 301281.SZ) recently held a special international registration conference. Senior management, the R&D team, and international registration experts gathered together to jointly discuss and map out implementation strategies for the international registration of the company's multiple products, thereby providing robust product support for the continuous growth of Keyuan Pharmaceutical's export revenue.
Against the backdrop of intensifying global pharmaceutical market competition, Keyuan Pharmaceutical has steadily advanced in key therapeutic areas such as diabetes, anesthesia, cardiovascular diseases, and mental health conditions—thanks to its robust R&D capabilities, impeccable product quality, and reliable large-scale manufacturing capacity. By simultaneously strengthening its presence in both domestic and international markets, the company continues to achieve new milestones, with its export share steadily expanding.
The company's core products have successively obtained the EU CEP certificate and have passed official pharmaceutical regulatory approvals from multiple countries, including the U.S. FDA, Japan’s PMDA, and South Korea’s MFDS, showcasing the high quality and international competitiveness of the company’s offerings—and providing a strong foundation for the company’s expansion into global markets.
The meeting emphasized that internationalization is one of Keyuan Pharmaceutical's key growth strategies. Accelerating the registration of the company's additional API products in global markets is crucial for enhancing the company's brand influence, expanding sales channels, and boosting export revenues.
The meeting noted that the company will continue to increase investment in product development and process optimization, striving to enhance product quality and technical capabilities while ensuring compliance with international regulatory and market registration requirements. At the same time, the company will integrate both internal and external resources to accelerate the international registration process for multiple products, thereby supporting the company’s deepening global expansion strategy.
The convening of this special international registration conference marks a solid step forward for Keyuan Pharmaceutical on its journey toward global expansion. As more of the company’s products steadily secure successful registration in international markets, Keyuan will further strengthen its position in the global arena, paving the way for a new wave of sales growth and deeper market penetration. Meanwhile, the company’s global strategic layout will reach an even higher level of sophistication and reach.
Latest News
Address: No. 26, Keyuan Street, Shanghe County, Jinan City, Shandong Province
Free Service Hotline